Global Triple Negative Breast Cancer (TNBC) Market Insight, Epidemiology and Market Forecast 2016-2018 & 2027 - ResearchAndMarkets.com

December 5, 2018

DUBLIN--(BUSINESS WIRE)--Dec 5, 2018--The “Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology and Market Forecast” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology and Market Forecast-2027′ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of TNBC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Triple Negative Breast Cancer (TNBC) from 2016 to 2027 segmented by G8 markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Triple Negative Breast Cancer (TNBC) - Disease Understanding and Treatment Algorithm

The Triple Negative Breast Cancer (TNBC) market report gives the thorough understanding of the Triple Negative Breast Cancer by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Triple Negative Breast Cancer in the US, Europe, Japan and China.

Triple Negative Breast Cancer Epidemiology

The Triple Negative Breast Cancer (TNBC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every G8 Countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

Key Topics Covered:

1. Key Insights

2. Triple Negative Breast Cancer Market Overview at a Glance

3. Disease Background and Overview: Triple Negative Breast Cancer

4. Unmet Needs

5. Epidemiology and Patient Population

6. Country Wise-Epidemiology of TNBC

7. Treatment Practices

8. Marketed Drug Analysis

9. Emerging Therapies

10. Triple Negative Breast Cancer [TNBC]: G8 Countries Market Analysis

11. Market Outlook by Country

12. Market Drivers

13. Market Barriers

14. Appendix

Companies Mentioned

AstraZeneca Clovis Oncology Hoffman La Roche Immunomedics Merck Pfizer/Astellas Roche Tesaro

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/b2w77r/global_triple?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181205005829/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Breast Cancer Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/05/2018 04:05 PM/DISC: 12/05/2018 04:05 PM


Update hourly